Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Vivus Wins FDA Approval


Amgen, Furiex, Takeda face rejection while Salix and Progenics get delayed.

MINYANVILLE ORIGINAL Vivus (VVUS) shareholders got a piece of good news late last week when the Food and Drug Administration approved the company's drug Stendra for erectile dysfunction. But another impotence pill is not the news that's going to have a big impact on this stock. Cowen Group analyst Simos Simeonidis estimates the drug may fetch $300 million if Vivus licenses or sells it to another company. Vivus doesn't have a sales force to sell the pill and it needs to focus on the big prize, which is winning US approval of its diet pill Qnexa. Investors were anticipating a decision on market clearance in April but the FDA delayed doing so until July 17. "The majority of the value associated with Vivus still lies with Qnexa," Leerink Swann analyst Steve Yoo says.

In other news in April, Amgen's (AMGN) attempt to win expanded use for its bone-healing drug Xgeva was rejected by the FDA. The agency said risks outweighed the benefits for patients with advanced prostate cancer. Xgeva is an important new product to Amgen with fast-growing sales. The rejection news was expected and Amgen shares actually rose slightly after the disclosure. A diabetes treatment developed by Furiex Pharmaceuticals (FURX) and Takeda (TKPYY.PK) also was rejected in April. (Furiex shares tanked on the news.) The FDA delayed a decision on expanded use of Relistor, marketed by Salix Pharmaceuticals (SLXP) and Progenics Pharmaceuticals (PGNX). Finally, Gilead Sciences (GILD) and Abbott Laboratories (ABT) are the big winners following the release of study results for experimental hepatitis C drugs. Gilead, in particular, is seen by Wall Street as the company to beat for a much-improved, next-generation hepatitis treatment. Shares of Gilead are up more than 26% this year, trading Monday at $51.76.

(See: Vivus Awaits Decisions on Two Drug Approvals in April.)

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos